News archive
News
Older news are available in Swedish.
All
AllUncategorized20242025
Publication of rights issue material
PharmaLundensis rights issue is available 13 -27 february. Message from the CEO Memorandum Feb 2025...
Carries out a rights issue of up to approx. MSEK 14.4
PharmaLundensis press release ENG At the board meeting of PharmaLundensis AB (publ) (“PharmaLundensis” or the...
Positive results in animal toxicology tests with Phal-501
The pilot animal toxicology study with Phal-501 in mice has now been completed. The study...
Publication of patent application for Phal-501
The European Patent Office (EPO) has now published PharmaLundensis’ patent application that protects Phal-501 and...
Now performing toxicological tests on mice with Phal-501
PharmaLundensis is now performing pilot in-vivo toxicological tests on mice with Phal-501. The study examines ...
Phal-501 also binds cadmium
Recent tests have shown that Phal-501 also binds cadmium. The binding is strong and dose-dependent...
Positive patent notice for Phal-501
PharmaLundensis has now received a review report from the PCT authority regarding the company’s mercury-binding...